An international team of researchers, led by the University of Vienna and the Helmholtz Institute for Pharmaceutical Research ...

MRSA was once eradicated reliably by vancomycin (Vancocin AE), an antibiotic of the glycopeptide class. With time, the MRSA bacteria became resistant to vancomycin and vancomycin-resistant ...

Q1 2025 Earnings Call Transcript May 13, 2025 Operator: Greetings and welcome to the Acurx Pharmaceuticals First Quarter 2025 Financial Results and Business Update. At this time, all participants are ...

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today ...

Once MRSA infection is diagnosed, limited options are available for treatment. Vancomycin (Vancocin ®), a glycopeptide antibiotic, is the drug of choice. The oral form of vancomycin is poorly ...

Researchers have discovered saarvienin A, a novel glycopeptide antibiotic from a rare earth mine bacterium. It shows potent ...

Workflows incorporating multiple AI tools have led to significant discoveries and clinical trials for drug candidates, including a new class of antibiotics effective against MRSA and VRE.

Armata Pharma reports positive data from phase 1b/2a diSArm study of intravenously administered AP-SA02 to treat S. aureus bacteremia: Los Angeles Tuesday, May 20, 2025, 17:00 Hrs ...

Antimicrobial-resistant (AMR) “superbugs” contribute to more than 4.5 million deaths globally per year and threaten to make ...